Statin Use for the Primary Prevention of Cardiovascular Disease in Adults

Применение статинов для первичной профилактики сердечно-сосудистых заболеваний у взрослых
Roger Chou, Rongwei F. Fu, Maros Ferencik, Amy G. Cantor, Tracy Dana, Jesse Wagner, Azrah Y. Ahmed
2022-08-23

cardiovascular diseasemyocardial infarctionprimary preventionrandomized clinical trialsstatin therapy
Importance: A 2016 review for the US Preventive Services Task Force (USPSTF) found use of statins for primary prevention of cardiovascular disease (CVD) was associated with reduced mortality and cardiovascular outcomes. Objective: To update the 2016 review on statins for primary prevention of CVD to inform the USPSTF. Data Sources: Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews (to November 2021); surveillance through May 20, 2022. Study Selection: Randomized clinical trials on statins vs placebo or no statin and statin intensity in adults without prior cardiovascular events; large cohort studies on harms. Data Extraction and Synthesis: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. Main Outcomes and Measures: All-cause and cardiovascular mortality, myocardial infarction, stroke, composite cardiovascular outcomes, and adverse events. Results: Twenty-six studies were included: 22 trials (N = 90 624) with 6 months to 6 years of follow-up compared statins vs placebo or no statin, 1 trial (n = 5144) compared statin intensities, and 3 observational studies (n = 417 523) reported harms. Statins were significantly associated with decreased risk of all-cause mortality (risk ratio [RR], 0.92 [95% CI, 0.87 to 0.98]; absolute risk difference [ARD], -0.35% [95% CI, -0.57% to -0.14%]), stroke (RR, 0.78 [95% CI, 0.68 to 0.90]; ARD, -0.39% [95% CI, -0.54% to -0.25%]), myocardial infarction (RR, 0.67 [95% CI, 0.60 to 0.75]; ARD, -0.85% [95% CI, -1.22% to -0.47%]), and composite cardiovascular outcomes (RR, 0.72 [95% CI, 0.64 to 0.81]; ARD, -1.28% [95% CI, -1.61% to -0.95%]); the association with cardiovascular mortality was not statistically significant (RR, 0.91 [95% CI, 0.81 to 1.02]; ARD, -0.13%). Relative benefits were consistent in groups defined by demographic and clinical characteristics, although data for persons older than 75 years were sparse. Statin therapy was not significantly associated with increased risk of serious adverse events (RR, 0.97 [95% CI, 0.93 to 1.01]), myalgias (RR, 0.98 [95% CI, 0.86 to 1.11]), or elevated alanine aminotransferase level (RR, 0.94 [95% CI, 0.78 to 1.13]). Statin therapy was not significantly associated with increased diabetes risk overall (RR, 1.04 [95% CI, 0.92 to 1.19]), although 1 trial found high-intensity statin therapy was significantly associated with increased risk (RR, 1.25 [95% CI, 1.05 to 1.49]). Otherwise, there were no clear differences in outcomes based on statin intensity. Conclusions and Relevance: In adults at increased CVD risk but without prior CVD events, statin therapy for primary prevention of CVD was associated with reduced risk of all-cause mortality and CVD events. Benefits of statin therapy appear to be present across diverse demographic and clinical populations, with consistent relative benefits in groups defined by demographic and clinical characteristics.
1
Among adults without prior cardiovascular events, statins reduced all-cause mortality versus placebo or no statin (RR, 0.92; ARD, -0.35%).
2
Relative statin benefits were generally consistent across demographic and clinical subgroups, but evidence was sparse for adults older than 75 years.
3
Statin use reduced stroke risk (RR, 0.78; ARD, -0.39%) and myocardial infarction risk (RR, 0.67; ARD, -0.85%) in primary prevention trials.
4
Statins reduced composite cardiovascular outcomes (RR, 0.72; ARD, -1.28%), while the reduction in cardiovascular mortality was not statistically significant.
5
The updated review included 22 statin trials involving 90,624 participants, one statin-intensity trial, and three observational studies assessing harms.

Statin therapy for primary prevention of cardiovascular disease in adults without prior cardiovascular events

Effects of statin use on mortality, cardiovascular outcomes, and adverse events

Publication Details
Publication Date
2022-08-23
Journal
Publisher
ISSN
Cited by
298
Access Type
Author Information
Authors
Roger Chou
Rongwei F. Fu
Maros Ferencik
Amy G. Cantor
Tracy Dana
Jesse Wagner
Azrah Y. Ahmed
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%